Delegate Login:
Lost password?
Request a reminder from conference@erbi.co.uk

BioPartnering Exchange Sponsors

ERBI's BioPartnering Exchange could not take place without its sponsors - their support helps drive the service we provide through the event and we extend our thanks to them.

Chesterford Research Park

Chesterford Research Park is a 250-acre site with a 30-acre development zone, a new 22,000 sq ft central facilities centre, Victorian country house, seven-hole par three golf course, several lakes, an arboretum and a growing community of science-based companies. When complete the park will comprise 600,000 sq ft of R&D facilities within a low density, landscaped environment.

History and objectives Chesterford Research Park is a joint venture between Morley Fund Management, part of Aviva plc, and The Churchmanor Estates Company plc - a specialist development company. The developers have been recognised internationally for their visionary approach to the park and all developments are supported by an agreed masterplan.

Progress to date For over 50 years, Chesterford has been a single occupier research location but since acquisition in July 2000, the developers have worked extensively to prepare the park for multiple occupancy. The development has advanced significantly with the completion of the first phase of additional buildings:

  • A new 25,000 sq ft laboratory and office building pre-let as the UK headquarters for Medivir.
  • The new 22,000 sq ft Nucleus building with: conference and meeting rooms, a high-spec gym/ health suite and restaurant/bar , convenience shop and social bar
  • New road infrastructure providing 250,000 sq ft of immediate development plots.
  • Planning consent for three phase two buildings totalling approximately 100,000 sq ft.

    The developers commitment to investing in and building a central facilities suite as part of the first phase of new buildings is a clear illustration of their long-term vision to make Chesterford a truly unique place in the Cambridge region.


    Park facilities

    In addition to offering a unique parkland setting and access to first-class centralised facilities, companies at Chesterford can benefit from:

  • On-site Park Manager
  • Specialist manned 24-hour security and reception for access into the park
  • Excellent road (M11) and rail links to London and Cambridge. The park is 21 miles from Stansted Airport.
  • A green transport plan providing park vehicle links to nearby stations
  • An extremely flexible design and fit out approach to accommodate occupiers' specifications and extensive plant and servicing requirements
  • An established and growing community spirit


    Companies on the park

    The United Kingdom Science Park Association (UKSPA), Arakis, BioFocus, Biotica, Cellzome, Medivir, Solexa and The Wellcome Trust.


    Contact Martin Sylvester
    Direct: +44(0) 1473 215854
    ms@churchmanor.com
    www.churchmanor.com
    www.chesterfordresearchpark.com

     

    UKTI

    UK Trade & Investment, the governmental body that helps companies trade overseas and encourage investment in the UK, has a team on hand to help companies invest in the UK. The organisatioon arranges trade missions to key industry events, provides expert market research on overseas opportunities and utilises its staff in the 200 UK embassies throughout the world to develop key contacts and host networking events.

    The UK Trade & Investment biotechnology team also hosts partnering events such as Biotechnology Business Exchange which was held in October 2004 to complement the International BioPartnering event in London. The event was a great success, with comapnies from New Zealand, Australia and the USA meeting counterparts from around the UK.

    The UK Trade & Investment Biotechnology Sector Team has helped comapnies find licensing and development opportunities in areas as diverse as bioinformatics, recombinent proteins used for the treatment of Alzheimer's and Parkinson's.

    To find out more information on how they can assist your organisation, e mail: biotech-info@uktradeinvest.gov.uk, telephone +44 (0)207 215 8000 or visit www.uktradeinvest.gov.uk/ukti/biotechnology and register on our portal website.

    UK Trade & Invest is extremely proud to once again be a major sponsor of ERBI's BioPartnering Exchange and wish it every success.

     

    Abingworth Management Ltd

    Abingworth was founded in 1973 and is a key player among life science venture capital investors with offices in London, Cambridge (UK), Menlo Park, California and Waltham, Massachusetts.
    Specialising in life science and biomedical companies, Abingworth now has funds under management of over $750 million and 25 staff including experienced professionals with operational, venture capital and public market investment expertise.
    The company has backed more than 90 life science/medical firms, most of which have gone public or been acquired. Abingworth is a strongly science driven investment organisation that is prepared to take on substantial technical risk.
    The management team has many years of operating experience and can actively assist scientific entrepreneurs in the development of their ideas into successful companies. Abingworth has the experience and resources to assist companies at any stage of development and take them beyond the IPO stage.
    Website: www.abingworth.com
    Email: info@abingworth.com



    BTG

    BTG acquires rights to early stage pharmaceuticals and other medical technologies from a global network of corporations, universities and research institutions. We apply resources, including finance, intellectual property and project management skills to fund and manage outsourced preclinical and clinical development programs. We then commercialize the technologies by licensing to pharmaceutical or device companies, or by creating companies to exploit them. Our pipeline comprises around 50 assets at varying stages of development, contributing to an increasing range of products marketed by our licensees. BTG operates from London, Philadelphia and Tokyo. For further information, visit www.btgplc.com

     

    Finance and Regulatory Advisory Service

    ERBI's BioPartnering Exchange has been generously supported by FRAS, the Finance and Regulatory Advisory Service.  FRAS is sponsored by EEDA and supported by Babraham Bioscience Technologies, ERBI and Medilink East.  FRAS serves small and medium sized biotech and medtech companies in the East of England through targeted events, co-ordination and signposting of appropriate advice resources relevant to the various financial and regulatory issues arising over the course of a company’s evolution.

     

    		•